- Home
- CDRE vs DMAC Comparison
CDRE vs DMAC Comparison
Compare CDRE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- DMAC
- Stock Information
- Founded
- CDRE 2012
- DMAC 2000
- Country
- CDRE United States
- DMAC United States
- Employees
- CDRE N/A
- DMAC N/A
- Industry
- CDRE Industrial Specialties
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- DMAC Health Care
- Exchange
- CDRE Nasdaq
- DMAC Nasdaq
- Market Cap
- CDRE 1.3B
- DMAC 310.1M
- IPO Year
- CDRE 2021
- DMAC N/A
- Fundamental
- Price
- CDRE $32.76
- DMAC $7.01
- Analyst Decision
- CDRE Buy
- DMAC Strong Buy
- Analyst Count
- CDRE 2
- DMAC 3
- Target Price
- CDRE $31.50
- DMAC $12.33
- AVG Volume (30 Days)
- CDRE 212.8K
- DMAC 440.7K
- Earning Date
- CDRE 11-05-2025
- DMAC 11-12-2025
- Dividend Yield
- CDRE 1.16%
- DMAC N/A
- EPS Growth
- CDRE N/A
- DMAC N/A
- EPS
- CDRE 0.93
- DMAC N/A
- Revenue
- CDRE $572,607,000.00
- DMAC N/A
- Revenue This Year
- CDRE $12.55
- DMAC N/A
- Revenue Next Year
- CDRE $7.70
- DMAC N/A
- P/E Ratio
- CDRE $35.16
- DMAC N/A
- Revenue Growth
- CDRE 7.66
- DMAC N/A
- 52 Week Low
- CDRE $27.07
- DMAC $3.19
- 52 Week High
- CDRE $40.28
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- CDRE 59.71
- DMAC 67.16
- Support Level
- CDRE $30.89
- DMAC $6.83
- Resistance Level
- CDRE $32.58
- DMAC $7.46
- Average True Range (ATR)
- CDRE 0.84
- DMAC 0.42
- MACD
- CDRE 0.28
- DMAC 0.08
- Stochastic Oscillator
- CDRE 97.16
- DMAC 79.58
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.